Show simple item record

dc.contributor.authorBertran, Kateri
dc.contributor.authorCriado, Miria Ferreira
dc.contributor.authorLee, Dong-Hun
dc.contributor.authorKillmaster, Lindsay
dc.contributor.authorSá e Silva, Mariana
dc.contributor.authorLucio, Eduardo
dc.contributor.authorWidener, Justin
dc.contributor.authorPritchard, Nikki
dc.contributor.authorAtkins, Emily
dc.contributor.authorMebatsion, Teshome
dc.contributor.authorSwayne, David E.
dc.contributor.otherProducció Animalca
dc.date.accessioned2020-04-14T15:21:56Z
dc.date.available2020-04-14T15:21:56Z
dc.date.issued2019-12-18
dc.identifier.citationBertran, Kateri, Miria Ferreira Criado, Dong-Hun Lee, Lindsay Killmaster, Mariana Sá e Silva, Eduardo Lucio, and Justin Widener et al. 2020. "Protection Of White Leghorn Chickens By Recombinant Fowlpox Vector Vaccine With An Updated H5 Insert Against Mexican H5N2 Avian Influenza Viruses". Vaccine 38 (6): 1526-1534. Elsevier BV. doi:10.1016/j.vaccine.2019.11.072.ca
dc.identifier.issn0264-410Xca
dc.identifier.urihttp://hdl.handle.net/20.500.12327/687
dc.description.abstractDespite decades of vaccination, surveillance, and biosecurity measures, H5N2 low pathogenicity avian influenza (LPAI) virus infections continue in Mexico and neighboring countries. One explanation for tenacity of H5N2 LPAI in Mexico is the antigenic divergence of circulating field viruses compared to licensed vaccines due to antigenic drift. Our phylogenetic analysis indicates that the H5N2 LPAI viruses circulating in Mexico and neighboring countries since 1994 have undergone antigenic drift away from vaccine seed strains. Here we evaluated the efficacy of a new recombinant fowlpox virus vector containing an updated H5 insert (rFPV-H5/2016), more relevant to the current strains circulating in Mexico. We tested the vaccine efficacy against a closely related subcluster 4 Mexican H5N2 LPAI (2010 H5/LP) virus and the historic H5N2 HPAI (1995 H5/HP) virus in White Leghorn chickens. The rFPV-H5/2016 vaccine provided hemagglutinin inhibition (HI) titers pre-challenge against viral antigens from both challenge viruses in almost 100% of the immunized birds, with no differences in number of birds seroconverting or HI titers among all tested doses (1.5, 2.0, and 3.1 log10 mean tissue culture infectious doses/bird). The vaccine conferred 100% clinical protection and a significant decrease in oral and cloacal virus shedding from 1995 H5/HP virus challenged birds when compared to the sham controls at all tested doses. Virus shedding titers from vaccinated 2010 H5/LP virus challenged birds significantly decreased compared to sham birds especially at earlier time points. Our results confirm the efficacy of the new rFPV-H5/2016 against antigenic drift of LPAI virus in Mexico and suggest that this vaccine would be a good candidate, likely as a primer in a prime-boostca
dc.format.extent9ca
dc.language.isoengca
dc.publisherElsevierca
dc.relation.ispartofVaccineca
dc.rightsAttribution 4.0 Internationalca
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.titleProtection of White Leghorn chickens by recombinant fowlpox vector vaccine with an updated H5 insert against Mexican H5N2 avian influenza virusesca
dc.typeinfo:eu-repo/semantics/articleca
dc.description.versioninfo:eu-repo/semantics/publishedVersionca
dc.rights.accessLevelinfo:eu-repo/semantics/openAccess
dc.embargo.termscapca
dc.subject.udc619ca
dc.identifier.doihttps://doi.org/10.1016/j.vaccine.2019.11.072ca
dc.contributor.groupSanitat Animalca


Files in this item

 

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/